Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT03788252

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Gumi Cha Medical Center (from the registry)
Registry
  • NCT NCT03788252
Other papers using this trial's data
  • Effects of AST-120 on muscle health and quality of life in chronic kidney disease patients: results of RECOVERY study Journal of cachexia, sarcopenia and muscle, 2022-02 DOI, PubMed 34862753, PMC8818653 In the PMC Open Access subset under CC BY.
  • Indoxyl Sulfate Might Play a Role in Sarcopenia, While Myostatin Is an Indicator of Muscle Mass in Patients with Chronic Kidney Disease: Analysis from the RECOVERY Study Toxins, 2022-09-23 DOI, PubMed 36287929, PMC9610577 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03788252. Randomized; no masking; primary purpose prevention. Start 2018-11-23 (actual); primary completion 2020-07-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease
Acronym
RECOVERY
Condition
Chronic Kidney Diseases
Intervention (Drug)
Renamezin
Lead sponsor
Gumi Cha Medical Center (class: other)

Record details

Record id
cardio:ct-nct03788252
Content hash
7404b7b7414a685043178b2f238b96cb84a13fba9a063c730120e5e370187c26